Research Analysts Issue Forecasts for LEXX Q4 Earnings

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Zacks Small Cap issued their Q4 2025 earnings per share (EPS) estimates for shares of Lexaria Bioscience in a research note issued on Tuesday, January 28th. Zacks Small Cap analyst J. Vandermosten anticipates that the company will post earnings of ($0.13) per share for the quarter. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.42) per share. Zacks Small Cap also issued estimates for Lexaria Bioscience’s FY2027 earnings at ($0.38) EPS.

Separately, HC Wainwright reduced their price target on Lexaria Bioscience from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, January 24th.

Lexaria Bioscience Price Performance

Shares of LEXX stock opened at $1.82 on Wednesday. The stock has a market cap of $31.94 million, a PE ratio of -3.64 and a beta of 0.98. The stock has a 50-day moving average of $2.14 and a 200-day moving average of $2.70. Lexaria Bioscience has a one year low of $1.43 and a one year high of $6.85.

Lexaria Bioscience (NASDAQ:LEXX) last announced its quarterly earnings results on Friday, January 10th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). Lexaria Bioscience had a negative net margin of 1,473.04% and a negative return on equity of 88.88%.

Insider Buying and Selling at Lexaria Bioscience

In other news, CEO Richard Christopher acquired 22,828 shares of the stock in a transaction on Monday, December 2nd. The shares were purchased at an average price of $2.24 per share, for a total transaction of $51,134.72. Following the transaction, the chief executive officer now directly owns 22,828 shares of the company’s stock, valued at approximately $51,134.72. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 26.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of LEXX. Renaissance Technologies LLC bought a new position in shares of Lexaria Bioscience in the second quarter worth $63,000. HighTower Advisors LLC acquired a new stake in Lexaria Bioscience in the third quarter valued at about $40,000. XTX Topco Ltd boosted its stake in Lexaria Bioscience by 47.8% in the third quarter. XTX Topco Ltd now owns 18,626 shares of the company’s stock valued at $57,000 after buying an additional 6,024 shares in the last quarter. Geode Capital Management LLC boosted its stake in Lexaria Bioscience by 31.0% in the third quarter. Geode Capital Management LLC now owns 150,391 shares of the company’s stock valued at $459,000 after buying an additional 35,608 shares in the last quarter. Finally, Byrne Asset Management LLC boosted its stake in shares of Lexaria Bioscience by 132.1% during the fourth quarter. Byrne Asset Management LLC now owns 13,000 shares of the company’s stock valued at $27,000 after purchasing an additional 7,400 shares in the last quarter. Institutional investors own 13.06% of the company’s stock.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.